In older advanced CKD patients, beta-blocker use raised death risk, while ACEI/ARB use lowered risks of both dialysis initiation and death.
How do clinical factors and cardiovascular medications (beta-blockers, ACEI/ARB) affect the risk of death and dialysis initiation in older patients with advanced chronic kidney disease?
In older patients with advanced CKD, ACEI/ARB use is associated with improved outcomes (lower risk of death and dialysis), while beta-blocker use and comorbidity burden are associated with increased mortality.
Absolute Event Rate: 0% vs 0%
In older patients with advanced CKD, comorbidity burden and beta-blocker use were associated with an increased risk of death, whereas ACEI/ARB use was linked to a lower likelihood of both dialysis initiation and death. These findings highlight the importance of a comprehensive, multidimensional approach that integrates clinical, functional, and therapeutic factors to better inform individualised care and enhance outcomes in this population.
Lauar et al. (Sun,) reported a other. In older advanced CKD patients, beta-blocker use raised death risk, while ACEI/ARB use lowered risks of both dialysis initiation and death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: